Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease (HBV VIP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01531075|
Recruitment Status : Unknown
Verified June 2012 by Ohad Etzion, Soroka University Medical Center.
Recruitment status was: Recruiting
First Posted : February 10, 2012
Last Update Posted : June 7, 2012
|Condition or disease||Intervention/treatment|
|Inflammatory Bowel Disease||Biological: ENGERIX-B (HBV Vaccine) Biological: Sci-B-Vac|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||75 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||March 2013|
Biological: ENGERIX-B (HBV Vaccine)
ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
Other Name: ENGERIX-B
Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
- protective level of anti HBs antibodies [ Time Frame: 1 month after the last does of vaccine ]
Antibody titer >10 IU/ml 30 days following last vaccine dose will be considered protective.
In the work done by Altunoz et al., titer rate below 10 IU was observed in 40% of the patients, while 40% of the patients achieved a rate of above 100 IU. Therefore, we can estimate that the geometric mean of distribution is approx. 50 IU. A sample size of 37 patients in each group achieves a power of 80% to detect a ratio above 1.37 between the two vaccinated groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531075
|Contact: Ohad Etzion, MDfirstname.lastname@example.org|
|Beer- Sheva, Israel, 84101|
|Contact: Ayala Dvir, M.Sc +972-86244245|
|Sub-Investigator: Olga Abel, MD|
|Principal Investigator:||Ohad Etzion, MD||Soroka UMC|